
BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Elevate Now secures Rs 18 Cr seed funding to build Indiaâ??s first clinical weight loss platform

09 February 2026 | News

Newly raised capital will be deployed towards strengthening the companyâ??s technology platform



Elevate Now, a doctor-led, root-cause-driven clinical weight loss platform, has raised Rs 18 crore in seed funding, led by Physis Capital, with participation from Inflection Point Ventures and Titan Capital.

India today has over 340 million people with a BMI above 25, yet most weight loss solutions rely on diets, gyms or influencer-led programs that struggle to deliver durable results. Elevate Now works on diagnosing underlying drivers for weight gain such as insulin resistance, inflammation and hormonal imbalances, and then delivering personalised treatment under medical supervision rather than generic calorie restriction.

The platform operates a fully online, subscription-based model offering programs ranging from 3 to 24 months. Each user is assigned a physician trained in obesity medicine, supported by blood diagnostics, continuous glucose monitoring data and a dedicated health coach. Where clinically appropriate, treatment includes responsible, doctor-supervised GLP-1 or relevant obesity medicine-based therapies, with protocols designed to prioritise safety, sustainability and long-term adherence.

The Bengaluru-based startup has onboarded over 30,000 paying users to date. Users have recorded an average weight loss of approximately 10 kilograms over six months. Its focus on long-term outcomes has resulted in a 90 percent weight maintenance rate six months after users complete their weight loss phase, significantly higher than industry benchmarks. Between April 2025 and January 2026, Elevate Now reported average month on month revenue growth of 17 percent.

The newly raised capital will be deployed towards strengthening the company’s technology platform, expanding proprietary clinical research, developing medicinal and nutritional supplements, and building next-generation personalisation systems to improve outcomes at scale.